Ardelyx
32
3
5
25
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
3.1%
1 terminated/withdrawn out of 32 trials
96.2%
+9.6% vs industry average
38%
12 trials in Phase 3/4
52%
13 of 25 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (32)
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
Role: lead
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Role: lead
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
Role: lead
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
Role: lead
Assessing Tenapanor as a Treatment of CF-related Constipation.
Role: collaborator
Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation
Role: collaborator
Tenapanor in Synucleinopathy-Related Constipation
Role: collaborator
An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
Role: lead
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Role: lead
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
Role: lead
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
Role: lead
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
Role: lead
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
Role: lead
Dose Finding Study to Treat High Phosphate Levels in the Blood.
Role: lead
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
Role: lead
An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
Role: lead
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
Role: lead
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
Role: lead
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Role: lead
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Role: lead